SCHEMBL10189221

SCHEMBL10189221

CCc1ccc2c(CC)n[nH]c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.47
FGFR1 P11362 1/20 0.43
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
PTK2B Q14289 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GSK3B P49841 4/20 0.38
MAP2K4 P45985 2/20 0.37
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37
TP53 P04637 1/20 0.36
DAO P14920 1/20 0.36
IDO1 P14902 1/20 0.35
PRMT5 O14744 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7978106 0.85 HTR1D (0.41) KIF11FGFR1MEN1NPC1ALDH1A1
SCHEMBL27381558 0.82 HPGD (0.47) MEN1ALDH1A1LMNAGAAHPGD
SCHEMBL91579 0.81 PDPK1 (0.55) KIF11FGFR1MEN1NPC1ALDH1A1
SCHEMBL130781 0.81 ITK (0.47) KIF11SMN1; SMN2MAP2K4PDE3BPDE3A
SCHEMBL8348438 0.81 KIF11 (0.47) KIF11FGFR1MEN1NPC1ALDH1A1
SCHEMBL11388 0.80 PDPK1 (0.58) ALDH1A1GSK3BPDE3BPDE3AIDO1
SCHEMBL5790250 0.80 PDE3B (0.36) FGFR1GSK3BPDE3BPDE3AGRM4
SCHEMBL16095565 0.80 AXL (0.50) FGFR1MEN1KMT2AGSK3BPDE3B
SCHEMBL5677771 0.80 MAP2K4 (0.51) GSK3BMAP2K4
SCHEMBL176792 0.80 PDPK1 (0.54) FGFR1ALDH1A1GAAHPGDGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778953-B2 Inhibitors of P38 map kinase CHROMA THERAPEUTICS LTD. (GB) 2014-07-15 US disclosed
US-8148531-B2 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2012-04-03 US disclosed
US-20090203711-A1 Inhibitors of P38 Map Kinase CHROMA THERAPEUTICS LTD. (GB) 2009-08-13 US disclosed
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CHROMA THERAPEUTICS LTD. (GB) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203711-A1 Inhibitors of P38 Map Kinase MAPK1, MAPK3, CNKSR1 KIF11 4375/4885FGFR1 1936/4885MEN1 4577/4885
US-20090131461-A1 Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity CDK1, AURKC, CSNK1G3 KIF11 2164/4885FGFR1 1707/4885MEN1 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.